Arcadia Biosciences Announces Stock Offering

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Jun 12 2026

0mins

RKDA-1.31%

Explore Agentic TradingLet AI Trade for You

Source: NASDAQ.COM

Stock Offering Announcement: Arcadia Biosciences has entered into agreements to sell 3.88 million shares of common stock and Series A-1 and A-2 preferred investment options, with expected gross proceeds of approximately $4 million, indicating a proactive approach to financing.
Clear Use of Proceeds: The net proceeds from this offering will be utilized for working capital and general corporate purposes, reflecting the company's strategic intent to expand operations and enhance financial flexibility.
Negative Market Reaction: Despite the offering price set at $1.03 per share, RKDA's stock fell by 3.74% in the latest trading session and further declined by 5.61% in after-hours trading, signaling investor concerns regarding the company's outlook.
Investor Attention on Expiration: The Series A-1 options expire five years after shareholder approval, while the Series A-2 options expire 24 months after the effectiveness of the resale registration statement, necessitating investor awareness of these timelines and their implications for future financing.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RKDA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on RKDA

About RKDA

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Arcadia Biosciences Closes Private Placement Raising $4 Million

Jun 13 2026Newsfilter

Financing Size: Arcadia Biosciences has successfully completed a private placement of 3,883,496 shares of common stock, raising approximately $4 million, indicating the company's active engagement in capital markets and its financing capabilities.
Investment Options Details: The financing includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately exercisable, enhancing investor flexibility.
Use of Proceeds: The company intends to utilize the proceeds for working capital and general corporate purposes, which will support the development and marketing of its innovative products, further solidifying its competitive position in the wellness product sector.
Compliance Statement: The securities offered were conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious approach to compliance and ensuring future capital operations adhere to relevant laws and regulations.

Arcadia Biosciences Announces Private Placement of Common Stock

Jun 12 2026seekingalpha

Private Placement Agreement: Arcadia Biosciences (RKDA) has entered into securities purchase agreements for a private placement of approximately 3.88 million shares of common stock at a price of $1.03 per share, aiming to raise about $4 million in gross proceeds, indicating the company's ability to access capital markets.
Clear Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, highlighting the company's focus on liquidity in the current market environment, which is intended to enhance its operational capacity and competitive position.
Transaction Timeline: The offering is expected to close on or about June 12, demonstrating the company's efficiency in responding to market demands and capital raising, which will help maintain flexibility in future business development.
Stock Price Impact: Following the announcement of the financing, RKDA's stock traded about 8% lower during pre-market hours on Friday, reflecting market caution regarding the financing plan and potentially affecting investor confidence in the company's future performance.